Treatment for RSV and Pneumonia in Infants

Initial Assessment and Severity Determination

Infants under 12 months, such as a 7-month-old, have attack rates of 35-40 per 1000 and tend to require hospitalization more frequently, indicating a high-risk category for severe disease 1
The presence of retractions is a critical indicator of increased severity and greater work of breathing in this age group 1
Key severity markers to assess include retractions and work of breathing 1, oxygen saturation levels 1, 2, respiratory rate and tachypnea 3, ability to maintain oral hydration 1, and presence of apnea or grunting 1

Maintain oxygen saturation above 90% using supplemental oxygen as needed, with low-flow oxygen via nasal cannula or face mask typically sufficient 1, 2
Ensure adequate hydration through oral fluids if tolerated, or via nasogastric or intravenous routes if the infant cannot maintain oral intake 1
Patients on oxygen therapy should have at least 4-hourly observations including oxygen saturation monitoring 2

RSV is the most common viral etiology of hospitalization for CAP in infants, and viral pathogens are responsible for up to 80% of pneumonia in children younger than 2 years 4, 5, 6
Antibiotics should be added only if bacterial co-infection is suspected based on clinical deterioration, increased systemic inflammation markers, specific radiographic findings, or no improvement within 48-72 hours of supportive care 3, 6
High-dose amoxicillin is the first-line oral therapy for presumed bacterial pneumonia, with ampicillin or ceftriaxone appropriate for hospitalized patients requiring parenteral therapy 3, 7

Hospitalization is warranted if the infant has hypoxemia, signs of severe respiratory distress, inability to maintain adequate oral intake, or concerns about family's ability to provide appropriate observation at home 1, 3
Escalation to intensive care is warranted if there is worsening respiratory distress, oxygen requirement of FiO2 ≥0.50, development of apnea or grunting, altered mental status, or sustained tachycardia 1

Children receiving adequate therapy should demonstrate clinical improvement within 48-72 hours, including decreased fever, improved respiratory rate, decreased work of breathing, stable oxygen saturation, and ability to maintain adequate oral intake 1, 3

High-risk infants should receive palivizumab prophylaxis during RSV season to decrease hospitalization risk by 39-78% 4, 8, 9

The CDC recommends nirsevimab, a long-acting monoclonal antibody, for all infants <8 months entering their first RSV season, administered as a single dose, as a significant advance over palivizumab 10

Clinical improvement should be evident within 48-72 hours of adequate supportive care, including decreased fever, improved respiratory rate, decreased work of breathing, stable oxygen saturation, and ability to maintain oral intake, and if no improvement occurs within this timeframe, reassess for bacterial co-infection 10